Abbott forms US pact to develop rapid acute renal failure urine test
This article was originally published in Clinica
Abbott has signed an exclusive agreement with Cincinnati Children's Hospital (CCH) to develop a urine test for acute renal failure (ARF) based on a marker that has recently emerged as a tool that could "transform the clinical approach to kidney disease". The biomarker, known as NGAL (neutrophil gelatinase-associated lipocalcin), was last year also exclusively licensed to Biosite to make serum and plasma-based tests (see Clinica No 1167, p 18).
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.